Topical omega-3 and omega-6 fatty acids for treatment of dry eye

Saadia Rashid, Yiping Jin, Tatiana Ecoiffier, Stefano Barabino, Debra A. Schaumberg, M. Reza Dana

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Objective: To study the efficacy of topical application of alpha-linolenic acid (ALA) and linoleic acid (LA) for dry eye treatment. Methods: Formulations containing ALA, LA, combined ALA and LA, or vehicle alone, were applied to dry eyes induced in mice. Corneal fluorescein staining and the number and maturation of corneal CD11b+ cells were determined by a masked observer in the different treatment groups. Real-time polymerase chain reaction was used to quantify expression of inflammatory cytokines in the cornea and conjunctiva. Results: Dry eye induction significantly increased corneal fluorescein staining; CD11b+ cell number and major histocompatibility complex Class II expression; corneal IL-1α and tumor necrosis factor α (TNF-α) expression; and conjunctival IL-1α, TNF-α, interferon γ, IL-2, IL-6, and IL-10 expression. Treatment with ALA significantly decreased corneal fluorescein staining compared with both vehicle and untreated controls. Additionally, ALA treatment was associated with a significant decrease in CD11b+ cell number, expression of corneal IL-1α and TNF-α, and conjunctival TNF-α. Conclusions: Topical ALA treatment led to a significant decrease in dry eye signs and inflammatory changes at both cellular and molecular levels. Clinical Relevance: Topical application of ALA omega-3 fatty acid may be a novel therapy to treat the clinical signs and inflammatory changes accompanying dry eye syndrome.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalArchives of Ophthalmology
Volume126
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Omega-6 Fatty Acids
alpha-Linolenic Acid
Linoleic Acid
Fluorescein
Interleukin-1
Staining and Labeling
Cell Count
Dry Eye Syndromes
Conjunctiva
Omega-3 Fatty Acids
Major Histocompatibility Complex
Interleukin-10
Cornea
Interferons
Interleukin-2
Real-Time Polymerase Chain Reaction
Interleukin-6
Tumor Necrosis Factor-alpha
Cytokines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Rashid, S., Jin, Y., Ecoiffier, T., Barabino, S., Schaumberg, D. A., & Dana, M. R. (2008). Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Archives of Ophthalmology, 126(2), 219-225. https://doi.org/10.1001/archophthalmol.2007.61

Topical omega-3 and omega-6 fatty acids for treatment of dry eye. / Rashid, Saadia; Jin, Yiping; Ecoiffier, Tatiana; Barabino, Stefano; Schaumberg, Debra A.; Dana, M. Reza.

In: Archives of Ophthalmology, Vol. 126, No. 2, 02.2008, p. 219-225.

Research output: Contribution to journalArticle

Rashid, S, Jin, Y, Ecoiffier, T, Barabino, S, Schaumberg, DA & Dana, MR 2008, 'Topical omega-3 and omega-6 fatty acids for treatment of dry eye', Archives of Ophthalmology, vol. 126, no. 2, pp. 219-225. https://doi.org/10.1001/archophthalmol.2007.61
Rashid, Saadia ; Jin, Yiping ; Ecoiffier, Tatiana ; Barabino, Stefano ; Schaumberg, Debra A. ; Dana, M. Reza. / Topical omega-3 and omega-6 fatty acids for treatment of dry eye. In: Archives of Ophthalmology. 2008 ; Vol. 126, No. 2. pp. 219-225.
@article{02548c0023e041c5a200c82cbab5b893,
title = "Topical omega-3 and omega-6 fatty acids for treatment of dry eye",
abstract = "Objective: To study the efficacy of topical application of alpha-linolenic acid (ALA) and linoleic acid (LA) for dry eye treatment. Methods: Formulations containing ALA, LA, combined ALA and LA, or vehicle alone, were applied to dry eyes induced in mice. Corneal fluorescein staining and the number and maturation of corneal CD11b+ cells were determined by a masked observer in the different treatment groups. Real-time polymerase chain reaction was used to quantify expression of inflammatory cytokines in the cornea and conjunctiva. Results: Dry eye induction significantly increased corneal fluorescein staining; CD11b+ cell number and major histocompatibility complex Class II expression; corneal IL-1α and tumor necrosis factor α (TNF-α) expression; and conjunctival IL-1α, TNF-α, interferon γ, IL-2, IL-6, and IL-10 expression. Treatment with ALA significantly decreased corneal fluorescein staining compared with both vehicle and untreated controls. Additionally, ALA treatment was associated with a significant decrease in CD11b+ cell number, expression of corneal IL-1α and TNF-α, and conjunctival TNF-α. Conclusions: Topical ALA treatment led to a significant decrease in dry eye signs and inflammatory changes at both cellular and molecular levels. Clinical Relevance: Topical application of ALA omega-3 fatty acid may be a novel therapy to treat the clinical signs and inflammatory changes accompanying dry eye syndrome.",
author = "Saadia Rashid and Yiping Jin and Tatiana Ecoiffier and Stefano Barabino and Schaumberg, {Debra A.} and Dana, {M. Reza}",
year = "2008",
month = "2",
doi = "10.1001/archophthalmol.2007.61",
language = "English (US)",
volume = "126",
pages = "219--225",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Topical omega-3 and omega-6 fatty acids for treatment of dry eye

AU - Rashid, Saadia

AU - Jin, Yiping

AU - Ecoiffier, Tatiana

AU - Barabino, Stefano

AU - Schaumberg, Debra A.

AU - Dana, M. Reza

PY - 2008/2

Y1 - 2008/2

N2 - Objective: To study the efficacy of topical application of alpha-linolenic acid (ALA) and linoleic acid (LA) for dry eye treatment. Methods: Formulations containing ALA, LA, combined ALA and LA, or vehicle alone, were applied to dry eyes induced in mice. Corneal fluorescein staining and the number and maturation of corneal CD11b+ cells were determined by a masked observer in the different treatment groups. Real-time polymerase chain reaction was used to quantify expression of inflammatory cytokines in the cornea and conjunctiva. Results: Dry eye induction significantly increased corneal fluorescein staining; CD11b+ cell number and major histocompatibility complex Class II expression; corneal IL-1α and tumor necrosis factor α (TNF-α) expression; and conjunctival IL-1α, TNF-α, interferon γ, IL-2, IL-6, and IL-10 expression. Treatment with ALA significantly decreased corneal fluorescein staining compared with both vehicle and untreated controls. Additionally, ALA treatment was associated with a significant decrease in CD11b+ cell number, expression of corneal IL-1α and TNF-α, and conjunctival TNF-α. Conclusions: Topical ALA treatment led to a significant decrease in dry eye signs and inflammatory changes at both cellular and molecular levels. Clinical Relevance: Topical application of ALA omega-3 fatty acid may be a novel therapy to treat the clinical signs and inflammatory changes accompanying dry eye syndrome.

AB - Objective: To study the efficacy of topical application of alpha-linolenic acid (ALA) and linoleic acid (LA) for dry eye treatment. Methods: Formulations containing ALA, LA, combined ALA and LA, or vehicle alone, were applied to dry eyes induced in mice. Corneal fluorescein staining and the number and maturation of corneal CD11b+ cells were determined by a masked observer in the different treatment groups. Real-time polymerase chain reaction was used to quantify expression of inflammatory cytokines in the cornea and conjunctiva. Results: Dry eye induction significantly increased corneal fluorescein staining; CD11b+ cell number and major histocompatibility complex Class II expression; corneal IL-1α and tumor necrosis factor α (TNF-α) expression; and conjunctival IL-1α, TNF-α, interferon γ, IL-2, IL-6, and IL-10 expression. Treatment with ALA significantly decreased corneal fluorescein staining compared with both vehicle and untreated controls. Additionally, ALA treatment was associated with a significant decrease in CD11b+ cell number, expression of corneal IL-1α and TNF-α, and conjunctival TNF-α. Conclusions: Topical ALA treatment led to a significant decrease in dry eye signs and inflammatory changes at both cellular and molecular levels. Clinical Relevance: Topical application of ALA omega-3 fatty acid may be a novel therapy to treat the clinical signs and inflammatory changes accompanying dry eye syndrome.

UR - http://www.scopus.com/inward/record.url?scp=39049160663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049160663&partnerID=8YFLogxK

U2 - 10.1001/archophthalmol.2007.61

DO - 10.1001/archophthalmol.2007.61

M3 - Article

VL - 126

SP - 219

EP - 225

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 2

ER -